<DOC>
	<DOC>NCT00577655</DOC>
	<brief_summary>The primary objective of this study is to evaluate the chronic-dose and efficacy of Albuterol-HFA-MDI relative to placebo in pediatric asthmatics.</brief_summary>
	<brief_title>Albuterol HFA MDI in Pediatric Participants With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Male and female child aged 411 years, inclusive Asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening. Hospitalization for acute asthma exacerbation greater than two years in 12 months prior to screening and/or received ER treatment or hospitalization for asthma exacerbation.</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pediatric, asthma, albuterol-HFA and Placebo</keyword>
</DOC>